A Case of Refractory Interstitial Lung Disease in Anti-MDA5–Positive Dermatomyositis That Improved After Switching to Tofacitinib

From the ∗Department of Rheumatology, Hiroshima City Hiroshima Citizens Hospital †Department of Rheumatology and Clinical Immunology, Hiroshima University Hospital, Hiroshima, Japan. The authors declare no conflict of interest. Correspondence: Hiroshi Oiwa, MD, Department of Rheumatology, Hiroshima City Hiroshima Citizens Hospital, 7-33 Moto-machi, Naka-ku, Hiroshima, Japan. E-mail: [email protected].